Purpose Of Review: The current review discusses allergen immunotherapy (AIT) safety in children.
Recent Findings: AIT is a well tolerated and effective treatment for pediatric allergic conditions. While mostly well tolerated, severe reactions and near fatal reactions may occur with subcutaneous immunotherapy (SCIT) once in every 160 000 visits. Sublingual immunotherapy (SLIT) is associated more with local side effects, but severe systemic reactions, including anaphylaxis, have been rarely reported. Providing informed consent, recognizing risk factors for severe systemic reactions, such as severe or uncontrolled asthma, and mitigating the risk of severe reactions are important components to improving the safety of AIT.
Summary: Overall, AIT is well tolerated in children, and data suggest that the incidence of systemic reactions in children receiving SCIT is no less than mixed populations of adult and pediatric patients. SLIT carries less risk for systemic reactions, and local oral site-application reactions are usually mild and resolve within 15 days of treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/ACI.0000000000000945 | DOI Listing |
J Neurophysiol
January 2025
Institute for Pathophysiology, West German Heart and Vascular Centre, University of Essen Medical School, University of Duisburg-Essen, Essen, Germany.
Low-Level Tragus Stimulation [LL-TS] as a non-invasive technique of vagus nerve stimulation [VNS] moves to the fore in autonomic nervous system [ANS] studies as a non-drug based, easy applicable tool. LL-TS triggering a complex systemic response may offer a broader cardioprotective potential than expected as a recent investigation outlined blood pressure [BP] reduction by LL-TS in patients with hypertension which is commonly related to imbalance of the ANS as several other cardiovascular diseases.
View Article and Find Full Text PDFInt J Nanomedicine
January 2025
Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Background: Melanoma is an aggressive form of skin cancer, and single-modality treatments often fail to prevent tumor recurrence and metastasis. Combination therapy has emerged as an effective approach to improve treatment outcomes.
Methods: In this study, we developed a multifunctional nanoplatform, MIL@DOX@ICG, utilizing MIL-101-NH(Fe) as a carrier to co-deliver the chemotherapeutic agent doxorubicin (DOX) and the photosensitizer indocyanine green (ICG).
Ther Adv Drug Saf
January 2025
Unidad Especializada en Tuberculosis, Servicio de Neumologia, Hospital Nacional Dos de Mayo, Lima, Perú.
The overlap of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Stevens-Johnson syndrome (SJS) caused by antituberculosis drugs represents an extremely rare event. This situation can manifest between 2 and 8 weeks after the first exposure to the medication. The overlap of these conditions can lead to atypical clinical manifestations, thus complicating the early diagnosis and the implementation of early treatment.
View Article and Find Full Text PDFJ Sci Med Sport
January 2025
Department of Health Promotion, School of Public Health, Faculty of Medical and Health Sciences, Sylvan Adams Sports Institute, Tel-Aviv University, Israel. Electronic address:
Objectives: The study aimed to examine the effects of exercise-induced muscle damage on running kinetics.
Design: Twenty-six adult recreational male runners performed 60 min of downhill running (-10 %) at 65 % of maximal heart rate. Running gait changes, systemic and localized muscle damage markers were assessed pre - and post-exercise induced muscle damage protocol.
Int J Biol Macromol
January 2025
Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, PR China; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan 646000, PR China. Electronic address:
As one of the most commonly used chemotherapeutic agents in clinical practice, cisplatin is unable to selectively accumulate in tumor tissue due to its lack of targeting ability, leading to increased systemic toxicities. Additionally, the effectiveness of monotherapy is greatly limited. Therefore, the development of new cisplatin-based drug delivery systems is essential to improve the effectiveness of tumor treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!